The University of Southampton
University of Southampton Institutional Repository

Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas

Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas

This phase 1 study evaluated frontline brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (BV1CHP; 6 cycles, then up to 10 cycles of brentuximab vedotin monotherapy) in 26 patients with CD301 peripheral T-cell lymphoma, including 19 with systemic anaplastic large cell lymphoma. All patients (100%) achieved an objective response, with a complete remission (CR) rate of 92%; none received a consolidative stem cell transplant. After a median observation period of 59.6 months (range, 4.6-66.0) from first dose, neither the median progression-free survival (PFS) nor the median overall survival (OS) was reached. No progression or death was observed beyond 35 months. The estimated 5-year PFS and OS rates were 52% and 80%, respectively. Eighteen of 19 patients (95%) with treatment-emergent peripheral neuropathy (PN) reported resolution or improvement of symptoms. Thirteen patients (50%) remained in remission at the end of the study, with PFS ranging from 37.81 to 66.01 months. Eight of these 13 patients received the maximum 16 cycles of study treatment. These final results demonstrate durable remissions in 50% of patients treated with frontline BV1CHP, suggesting a potentially curative treatment option for some patients. This trial was registered at www.clinicaltrials.gov as #NCT01309789.

0006-4971
2120-2124
Fanale, Michelle A.
af0a7fc2-6fd1-4812-aeec-8546555ddc8e
Horwitz, Steven M.
25c7caf8-d3d9-4119-82c9-b2cbc8eac18e
Forero-Torres, Andres
2b186d3b-e6f4-4760-b8d0-440134f95bf2
Bartlett, Nancy L.
c528a4a6-0972-484c-a765-9439d6da84f0
Advani, Ranjana H.
3aca77e5-e1b1-4ffb-b1bb-a7a703e0e15c
Pro, Barbara
7eee703c-a248-4929-b482-333bd6c1825d
Chen, Robert W.
a6b0e8d9-a493-43cb-b78f-c64ccb80d800
Davies, Andrew
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Illidge, Tim
50e3482f-405f-4534-8062-180bba1c1619
Uttarwar, Mayur
92320b6a-5a1e-40a4-857a-1a85d885ef23
Lee, Shih Yuan
16460cce-22af-4510-9740-09f7e7abd6db
Ren, Hong
2c169821-353c-47a9-9a98-a1b34f280d25
Kennedy, Dana A.
3e7355b2-4c97-4e1e-bd53-47f9779f8a5e
Shustov, Andrei R.
1088a40d-0ac8-4057-9cc5-dc187be603f1
Fanale, Michelle A.
af0a7fc2-6fd1-4812-aeec-8546555ddc8e
Horwitz, Steven M.
25c7caf8-d3d9-4119-82c9-b2cbc8eac18e
Forero-Torres, Andres
2b186d3b-e6f4-4760-b8d0-440134f95bf2
Bartlett, Nancy L.
c528a4a6-0972-484c-a765-9439d6da84f0
Advani, Ranjana H.
3aca77e5-e1b1-4ffb-b1bb-a7a703e0e15c
Pro, Barbara
7eee703c-a248-4929-b482-333bd6c1825d
Chen, Robert W.
a6b0e8d9-a493-43cb-b78f-c64ccb80d800
Davies, Andrew
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Illidge, Tim
50e3482f-405f-4534-8062-180bba1c1619
Uttarwar, Mayur
92320b6a-5a1e-40a4-857a-1a85d885ef23
Lee, Shih Yuan
16460cce-22af-4510-9740-09f7e7abd6db
Ren, Hong
2c169821-353c-47a9-9a98-a1b34f280d25
Kennedy, Dana A.
3e7355b2-4c97-4e1e-bd53-47f9779f8a5e
Shustov, Andrei R.
1088a40d-0ac8-4057-9cc5-dc187be603f1

Fanale, Michelle A., Horwitz, Steven M., Forero-Torres, Andres, Bartlett, Nancy L., Advani, Ranjana H., Pro, Barbara, Chen, Robert W., Davies, Andrew, Illidge, Tim, Uttarwar, Mayur, Lee, Shih Yuan, Ren, Hong, Kennedy, Dana A. and Shustov, Andrei R. (2018) Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. Blood, 131 (19), 2120-2124. (doi:10.1182/blood-2017-12-821009).

Record type: Article

Abstract

This phase 1 study evaluated frontline brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (BV1CHP; 6 cycles, then up to 10 cycles of brentuximab vedotin monotherapy) in 26 patients with CD301 peripheral T-cell lymphoma, including 19 with systemic anaplastic large cell lymphoma. All patients (100%) achieved an objective response, with a complete remission (CR) rate of 92%; none received a consolidative stem cell transplant. After a median observation period of 59.6 months (range, 4.6-66.0) from first dose, neither the median progression-free survival (PFS) nor the median overall survival (OS) was reached. No progression or death was observed beyond 35 months. The estimated 5-year PFS and OS rates were 52% and 80%, respectively. Eighteen of 19 patients (95%) with treatment-emergent peripheral neuropathy (PN) reported resolution or improvement of symptoms. Thirteen patients (50%) remained in remission at the end of the study, with PFS ranging from 37.81 to 66.01 months. Eight of these 13 patients received the maximum 16 cycles of study treatment. These final results demonstrate durable remissions in 50% of patients treated with frontline BV1CHP, suggesting a potentially curative treatment option for some patients. This trial was registered at www.clinicaltrials.gov as #NCT01309789.

Full text not available from this repository.

More information

Accepted/In Press date: 25 February 2018
e-pub ahead of print date: 10 May 2018

Identifiers

Local EPrints ID: 421498
URI: https://eprints.soton.ac.uk/id/eprint/421498
ISSN: 0006-4971
PURE UUID: ca7afac5-359b-43c9-9e0f-5c0b7d8c7a48

Catalogue record

Date deposited: 14 Jun 2018 16:30
Last modified: 13 Mar 2019 18:22

Export record

Altmetrics

Contributors

Author: Michelle A. Fanale
Author: Steven M. Horwitz
Author: Andres Forero-Torres
Author: Nancy L. Bartlett
Author: Ranjana H. Advani
Author: Barbara Pro
Author: Robert W. Chen
Author: Andrew Davies
Author: Tim Illidge
Author: Mayur Uttarwar
Author: Shih Yuan Lee
Author: Hong Ren
Author: Dana A. Kennedy
Author: Andrei R. Shustov

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×